---
title: Patient Outcomes of Clinic Transition From Face to Face Encounter to Telemedicine in Cystic Fibrosis
nct_id: NCT04402801
overall_status: COMPLETED
sponsor: University of Virginia
study_type: OBSERVATIONAL
primary_condition: Cystic Fibrosis
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04402801.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04402801"
ct_last_update_post_date: 2023-12-05
last_seen_at: "2026-05-12T06:29:12.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Patient Outcomes of Clinic Transition From Face to Face Encounter to Telemedicine in Cystic Fibrosis

**Official Title:** Impact on Patient Outcomes of Clinic Transition From Face to Face Encounters to Telemedicine in the Cystic Fibrosis (CF) Adult Population at UVA

**NCT ID:** [NCT04402801](https://clinicaltrials.gov/study/NCT04402801)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 140
- **Lead Sponsor:** University of Virginia
- **Conditions:** Cystic Fibrosis
- **Start Date:** 2020-06-01
- **Completion Date:** 2022-05-31
- **CT.gov Last Update:** 2023-12-05

## Brief Summary

Adult patients with Cystic Fibrosis who are seen at the specialty CF clinic at University of Virginia will be given an option to utilize telemedicine instead of in-person visits for standard clinic visits. Health information from standard of care visits including FEV1, exacerbations, leading to oral or intravenous antibiotics, laboratory results, hospitalization records, and responses to health questionnaires will be recorded for research purposes. Data collected for the research study will be compared to baseline and previous years to determine if there are any deleterious effects for those who transition to telemedicine clinic visits.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 90 Years
- **Sex:** ALL

```
Inclusion Criteria:

* Adult patients (18-year-old and older) with CF seen in the UVA adult CF clinic who agree to participate in the study.

Exclusion Criteria:

* Patients who cannot consent to the research study. In addition, prisoners will not be included.
```

## Arms

- **Standard of Care Telemedicine Cohort** — This cohort will have telemedicine visits in lieu of in-person clinic visits
- **Standard of Care In-Person Cohort**

## Primary Outcomes

- **FEV1 stability** _(time frame: 12 months)_ — A change of 10% or more in FEV1 percent predicted will be considered significant; FEV1 pre and pos covid telemedicine implementation will be compared

## Secondary Outcomes

- **Exacerbation rate** _(time frame: 12 months)_

## Locations (1)

- University of Virginia Health System, Charlottesville, Virginia, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of virginia health system|charlottesville|virginia|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04402801.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04402801*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*